Rina Diana Salurialam

Title: Rina Diana Salurialam: Innovator in Pharmaceutical Dosage Forms

Introduction

Rina Diana Salurialam is an accomplished inventor based in the United States. She has made significant contributions to the field of medicine and pharmaceuticals, particularly in the development of stable dosage forms for antitumor preparations. Her innovative work focuses on enhancing the stability and efficacy of pharmaceutical compounds.

Latest Patents

Rina holds a patent for a "Stable Dosage Form Of Etidronate-Cytarabine Conjugate, And Use Thereof." This invention relates to a novel dosage form that ensures the hydrolytic and physical stability of an antitumor preparation. The stable dosage form is a lyophilisate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, along with a stabilizer, which is a divalent metal salt. The molar ratio of stabilizer to conjugate ranges from 1:1 to 20:1. This formulation guarantees the stability of the conjugate during long-term storage and maintains the stability of solutions for parenteral administration during clinical use.

Career Highlights

Rina is currently associated with Maxwell Biotech Group Ltd., where she continues to advance her research in pharmaceutical innovations. Her work is pivotal in developing new therapeutic options for patients requiring antitumor treatments.

Collaborations

Rina collaborates with notable colleagues, including Ekaterina Alekseevna Ivanova and Alexander Karpeisky. These partnerships enhance her research capabilities and contribute to the advancement of pharmaceutical sciences.

Conclusion

Rina Diana Salurialam is a notable inventor whose work in stable dosage forms has the potential to significantly impact the field of medicine. Her innovative approaches to pharmaceutical formulations demonstrate her commitment to improving patient care through scientific advancements.